Evidence-based care has rightly become important for both health care commissioners and providers; increasingly the spotlight is being turned to palliative care services. The general verdict is that there is evidence to support some areas of practice, but there needs to be more, [1] [2] [3] [4] although acquiring this evidence presents considerable methodological difficulties.
In 1997, the Association for Palliative Medicine of Great Britain and Ireland (APM) established a Science Committee chaired by Professor Sam H Ahmedzai. Its purpose was to advise the APM on the scientific basis of palliative medicine; to document the existing evidence for palliative care; and to set priorities in seeking new evidence, particularly in relation to clinical interventions. Ultimately, and with the support of local research networks and other stakeholders, the Science Committee hopes to engender a national palliative medicine research programme.
When the phrases 'palliative care' and 'evidence' occur in the same sentence in journal articles, the focus is often on the effectiveness of services on populations rather than the effect of treatments on patients. [2] [3] [4] [5] The Science Committee's first objective was to address this imbalance, by establishing task groups to examine specific aspects of clinical practice, including clinical assessment as well as therapeutic interventions.
The task groups are each led by an APM member and can have up to six participants, drawn from any relevant specialty, but should include a trainee (specialist registrar) in palliative medicine. Each task group is allocated a member of the Science Committee who acts as advisor and facilitator. A prospective task group is invited to register a sharply focused clinical question, for example 'evidence for the use of bisphosphonates in metastatic bone pain' rather than 'the management of bone pain'. The task groups are asked to present a plan of their activity and to complete their work within 12 months. The APM supplies the task groups with a working budget to cover literature searches, mailing and travelling expenses. We also acknowledge the generous support of Macmillan Cancer Relief and Marie Curie Foundation for this and other Science Committee activities.
A crucial component of this activity is searching for evidence and recording the search strategies and information sources. This is vital to ensure that any conclusions are based on a systematic search and are seen to be valid. Some clinical scientists might argue that if the quoted evidence relating to an intervention is not the product of a randomized controlled clinical trial (RCT) then it is of little value. Palliative care is an area of practice where too few such trials have been published, and in the view of the Science Committee, it would be shortsighted to ignore all other forms of research literature. Furthermore, it could be argued that RCTs are inappropriate or unethical for some areas of clinical research 6, 7 and it would be wrong for palliative care to discard the fruits of well-designed and rigorously analysed qualitative studies. 8 We therefore contend that all published material is potentially useful evidence, provided that such evidence is subjected to critical analysis and interpreted in a universally understood manner. This approach can highlight some relatively unknown sources of good data in what are generally considered to be areas of clinical uncertainty. Conversely, it can reveal a dangerous lack of evidence in support of 'time-honoured' cherished practices, which may indeed have no scientific basis.
The Science Committee recommends that strict criteria be adopted, such as those proposed by Sackett, 9 which describe an evidence-based process for developing clinical guidelines. This system ranks evidence in the following categories: I = Large RCTs with clear-cut results. II = Small RCTs with uncertain results and moderate to high risk of error. III = Nonrandomized contemporaneous controls. IV = Nonrandomized historical controls. V = Case series without controls.
Task group leaders are encouraged to undertake training in searching and reviewing, such as that provided by the Cochrane Centre. 10 The Science Committee has links with PaPaS, the Cochrane group which co-ordinates systematic reviews of RCTs on pain, palliative care and supportive care. We are aware that besides the Cochrane collaboration, other agencies are undertaking reviews and writing guidelines, and we will try to avoid duplication with these wherever possible.
After the task group has completed its searches, it submits a short structured report to the Science Committee which contains: the original question and its relevance to palliative care; the search strategies and information sources used; key conclusions and the implications for current practice. This report is then sent to an expert referee, who should be a recognized authority in the field but need not be practising within palliative care, for an external commentary on the scope of the report and of the likely developments in the future. It is intended that the approved reports will be made available to APM members through its newsletter and to an international audience through the APM website. Finally, the task group is invited to submit a full scientific paper for publication detailing the critiqued evidence and including clinical guidelines based on this. We are pleased that Palliative Medicine has agreed to publish papers in this series, providing that they meet the journal's own criteria for scientific value.
At present four task groups have been established, to examine bisphosphonates in bone pain, antimuscarinic drugs in 'death rattle', opioids in dyspnoea and antifungal antibiotics in oral candidosis. In this issue of Palliative Medicine, the first task group paper appears, reviewing the evidence for the use of bisphosphonates in metastatic bone pain and offering succinct, practical clinical guidelines. 11 The conclusions can readily be incorporated into local palliative care guidelines to support evidence-based decision making in the management of bone pain. We are delighted that Professor Rob Coleman, an internationally acclaimed oncological researcher in the field of bone metastases, was the Science Committee's referee and has lent his support and critical approval to this paper.
Palliative care in the twenty-first century is rapidly developing into a scientifically based discipline, yet it needs to retain its humanely expressed clinical practice which has been its strength from its inception. Clinical guidelines will be increasingly important, to ensure that patients receive universally acceptable investigations and treatments, but they should never blindly replace individualized, bedside judgements by trained clinicians. We welcome ideas for new task group questions, and invite palliative medicine trainees and specialists, as well as colleagues from other disciplines, to make contact with us to accelerate our work.
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